Latest Stock Buy or Sell? Make More Informed Decisions!

High valuation, but paying a premium for a name that has scale and not many competitors. 

Removed from his portfolio not long ago on a stop loss. Long term, secular growth of anti-obesity drugs is still strong. Short-term, cyclical challenges. Quite leveraged to anti-obesity and diabetes, but LLY is more diversified.

Once negative sentiment dissipates, could see him getting back in. About 20-25% earnings growth, trading at 22x, so PEG is just under 1. Value is there, but sentiment not in its favour right now.

Long term, secular growth of anti-obesity drugs is still strong. More diversified than NVO, which he sold on a stop loss.

Fantastic earnings growth. Just bounced off 200-day MA (a good support level), and that's where he added recently. Paying about 32x forward PE for 35% expected growth, so the PEG ratio is reasonable. 

DeepSeek news concerned some investors, but does it make the products that NVDA does with the same broad customer base? Have to see over coming quarters and years.

Fell below 200-day MA in summer, he got stopped out. Would revisit the name once the dust settles. 30x forward PE for 20% earnings growth. Trying to base. Long-term AI sector thesis very much intact. The leader in its niche.

9% forecast growth rate, trading ~14x forward PE. Not a bad valuation to growth rate. Great chart of higher highs and higher lows. Outpacing S&P since late 2021. Pricing power and favourable demographics. Yield is 1.6%.

Continues to like it. Paying a premium, but for specific reasons. Trades at 31x forward PE for 15% earnings growth. Recent decline is a good chance to add. In Canada, demand is growing for value-priced essentials.

Likes US financials. Quietly up ~49% last 12 months. Just watch that's it's coming up to potential resistance around $50, which it hit in early 2022. If it breaks above, great sign; but might also bounce down below it. He owns GS. 

See his Top Picks.

Likes US financials. Likes its ability to really take advantage of increased M&A activity. See his Top Picks.

Likes US financials and thinks this name will do well. See his Top Picks.

These names will do well under the new administration and with de-regulation and pro-business policies. Environment ripe for increased M&A activity and increased investment-banking fees.

Generally likes the dividend payers, depending on the investor. Good if you're looking for income and steady growth. Be aware that a lot of the weighting is bunched around the Canadian banks, with energy companies following. Steady performance, value play. Dividend is fine and growth will be there.

Generally likes the dividend payers, depending on the investor. Good if you're looking for income and steady growth. Be aware that a lot of the weighting is bunched around the Canadian banks, with energy companies following. Steady performance, value play. Dividend is fine and growth will be there.

The S&P 500 index, but in Canadian dollars. Not expensive at 9 bps MER. But, as he's pointed out before, the S&P has about 37% bunched up around 10 names (with 8 of those being tech names). So you can think it's extremely diversified, but it's not. 

He's not saying not to own it, but you need to know what you're buying compared to what you already own in your portfolio.

Let's look at the chart, as the first thing you do is check the technical structure. Stock's not only come down, but also fallen below the 200-day MA. The 200-day MA, itself, is starting to go sideways and downwards. Weakening. Guided lower on earnings.

Expected earnings growth rate is very strong double digits, and the PE isn't bad at 27x. However, the chart's telling you something different. Chart for much of 2023 and 2024 had been sideways. Potential for regulation to come along and hurt profits.